372 related articles for article (PubMed ID: 15347586)
1. Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1.
Dirksen RT; Avila G
Biophys J; 2004 Nov; 87(5):3193-204. PubMed ID: 15347586
[TBL] [Abstract][Full Text] [Related]
2. The pore region of the skeletal muscle ryanodine receptor is a primary locus for excitation-contraction uncoupling in central core disease.
Avila G; O'Connell KM; Dirksen RT
J Gen Physiol; 2003 Apr; 121(4):277-86. PubMed ID: 12642598
[TBL] [Abstract][Full Text] [Related]
3. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor.
Avila G; Dirksen RT
J Gen Physiol; 2001 Sep; 118(3):277-90. PubMed ID: 11524458
[TBL] [Abstract][Full Text] [Related]
4. Reduced threshold for store overload-induced Ca
Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
[TBL] [Abstract][Full Text] [Related]
5. Calcitonin gene-related peptide restores disrupted excitation-contraction coupling in myotubes expressing central core disease mutations in RyR1.
Vega AV; Ramos-Mondragón R; Calderón-Rivera A; Zarain-Herzberg A; Avila G
J Physiol; 2011 Oct; 589(Pt 19):4649-69. PubMed ID: 21825032
[TBL] [Abstract][Full Text] [Related]
6. Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region.
Murayama T; Kurebayashi N; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
PLoS One; 2015; 10(6):e0130606. PubMed ID: 26115329
[TBL] [Abstract][Full Text] [Related]
7. Ca2+ release in muscle fibers expressing R4892W and G4896V type 1 ryanodine receptor disease mutants.
Lefebvre R; Legrand C; Groom L; Dirksen RT; Jacquemond V
PLoS One; 2013; 8(1):e54042. PubMed ID: 23308296
[TBL] [Abstract][Full Text] [Related]
8. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.
Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648
[TBL] [Abstract][Full Text] [Related]
9. Intracellular Ca2+ dynamics in malignant hyperthermia and central core disease: established concepts, new cellular mechanisms involved.
Avila G
Cell Calcium; 2005 Feb; 37(2):121-7. PubMed ID: 15589992
[TBL] [Abstract][Full Text] [Related]
10. Two central core disease (CCD) deletions in the C-terminal region of RYR1 alter muscle excitation-contraction (EC) coupling by distinct mechanisms.
Lyfenko AD; Ducreux S; Wang Y; Xu L; Zorzato F; Ferreiro A; Meissner G; Treves S; Dirksen RT
Hum Mutat; 2007 Jan; 28(1):61-8. PubMed ID: 16958053
[TBL] [Abstract][Full Text] [Related]
11. FKBP12 binding to RyR1 modulates excitation-contraction coupling in mouse skeletal myotubes.
Avila G; Lee EH; Perez CF; Allen PD; Dirksen RT
J Biol Chem; 2003 Jun; 278(25):22600-8. PubMed ID: 12704193
[TBL] [Abstract][Full Text] [Related]
12. Elevated resting [Ca(2+)](i) in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR.
Yang T; Esteve E; Pessah IN; Molinski TF; Allen PD; López JR
Am J Physiol Cell Physiol; 2007 May; 292(5):C1591-8. PubMed ID: 17182726
[TBL] [Abstract][Full Text] [Related]
13. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
14. A malignant hyperthermia-inducing mutation in RYR1 (R163C): consequent alterations in the functional properties of DHPR channels.
Bannister RA; Estève E; Eltit JM; Pessah IN; Allen PD; López JR; Beam KG
J Gen Physiol; 2010 Jun; 135(6):629-40. PubMed ID: 20479108
[TBL] [Abstract][Full Text] [Related]
15. Measurement of resting cytosolic Ca2+ concentrations and Ca2+ store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca2+ release channels.
Tong J; McCarthy TV; MacLennan DH
J Biol Chem; 1999 Jan; 274(2):693-702. PubMed ID: 9873004
[TBL] [Abstract][Full Text] [Related]
16. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease.
Lyfenko AD; Goonasekera SA; Dirksen RT
Biochem Biophys Res Commun; 2004 Oct; 322(4):1256-66. PubMed ID: 15336973
[TBL] [Abstract][Full Text] [Related]
17. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.
Tong J; Oyamada H; Demaurex N; Grinstein S; McCarthy TV; MacLennan DH
J Biol Chem; 1997 Oct; 272(42):26332-9. PubMed ID: 9334205
[TBL] [Abstract][Full Text] [Related]
18. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
19. Excitation--contraction uncoupling by a human central core disease mutation in the ryanodine receptor.
Avila G; O'Brien JJ; Dirksen RT
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):4215-20. PubMed ID: 11274444
[TBL] [Abstract][Full Text] [Related]
20. Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala.
Wehner M; Rueffert H; Koenig F; Olthoff D
Genet Test; 2003; 7(3):203-11. PubMed ID: 14641996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
